Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Clinica Baviera's net income from continuing operations for the
three
months ended in Jun. 2026 was €17.0 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Jun. 2026 was €64.8 Mil.
Clinica Baviera Net Income From Continuing Operations Historical Data
* Premium members only.
The historical data trend for Clinica Baviera's Net Income From Continuing Operations can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Clinica Baviera Net Income From Continuing Operations Chart
Clinica Baviera Net Income From Continuing Operations Calculation
Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.
Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €64.8 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Net Income From Continuing Operations of €64.8 Mil mean?
Clinica Baviera (XMAD:CBAV) has a Net Income From Continuing Operations of €64.8 Mil as of Jun. 2026. The total net income from continuing operations as record on a company's cash-flow statement. View historical data for Clinica Baviera and its competitors.
Is Clinica Baviera's Net Income From Continuing Operations too high?
Clinica Baviera's current Net Income From Continuing Operations is €64.8 Mil. Overall, Clinica Baviera has a GF Score™ of 100/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Clinica Baviera's Net Income From Continuing Operations compare to TMO and DHR?
Clinica Baviera's Net Income From Continuing Operations of €64.8 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Income From Continuing Operations for a Medical Diagnostics & Research company?
A good Net Income From Continuing Operations depends on the Medical Diagnostics & Research industry context. However, Net Income From Continuing Operations should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Income From Continuing Operations mean?
A high Net Income From Continuing Operations can signal that a stock is expensive relative to its fundamentals. The total net income from continuing operations as record on a company's cash-flow statement. View historical data for Clinica Baviera and its competitors. Clinica Baviera's current Net Income From Continuing Operations is €64.8 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Clinica Baviera stock overvalued right now?
Based on GuruFocus' analysis, Clinica Baviera (XMAD:CBAV) is currently considered Modestly Overvalued. The stock's GF Value™ is €44.74, compared to a current price of €56.40 — trading 26.1% above its estimated fair value. The current Net Income From Continuing Operations is €64.8 Mil. Clinica Baviera's overall GF Score™ is 100/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Income From Continuing Operations calculated?
Net Income From Continuing Operations is calculated from a company's financial statements. For Clinica Baviera (XMAD:CBAV), the current Net Income From Continuing Operations is €64.8 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Clinica Baviera (XMAD:CBAV) Overvalued in 2026?
Based on GuruFocus' analysis, Clinica Baviera stock appears to be overvalued.
The current stock price of €56.40 is trading 26.1% above its estimated GF Value™ of €44.74.
GuruFocus considers Clinica Baviera to be Modestly Overvalued.
Key valuation signals for XMAD:CBAV:
Net Income From Continuing Operations: €64.8 Mil
GF Value™: €44.74 vs. price of €56.40 (26.1% above fair value)
No single metric tells the full story. See the XMAD:CBAV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Clinica Baviera SA is a Spanish ophthalmology group that operates a network of eye clinics, primarily under the Clínica Baviera brand. It specializes in the diagnosis, treatment, and follow-up of vision disorders, offering refractive surgery for myopia, hyperopia, and astigmatism, as well as cataract surgery, presbyopia correction, glaucoma and retina treatments, and general ophthalmology services. The company serves private patients, with revenue generated mainly from surgical procedures and consultations, and it has expanded internationally, notably into Italy, Germany, Austria, and other European markets. Founded in Spain, it has grown through a combination of new clinic openings and acquisitions, and it is listed on the Spanish stock exchange. Its business model relies on a large network of owned clinics, in-house medical staff, and direct marketing to attract self-paying patients.
100GF Score
Get the complete analysis for XMAD:CBAV
Net Income From Continuing Operations is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XMAD:CBAV has been successfully added to your 
